schliessen

Filtern

 

Bibliotheken

Patients’ Willingness-to-Pay for an Alzheimer’s Disease Medication in Canada

BACKGROUNDAlzheimer's disease (AD) is a neurodegenerative disorder highlighted by progressive declines in cognition and function. OBJECTIVESThe aim of this article is to assess whether persons with AD would support out-of-pocket payment for an AD medication; to elicit the monthly dollar amounts they... Full description

Journal Title: The Patient - Patient-Centered Outcomes Research 2013, Vol.6(3), pp.161-168
Main Author: Oremus, Mark
Other Authors: Tarride, Jean-Eric , Pullenayegum, Eleanor , Clayton, Natasha , Raina, Parminder
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1178-1653 ; E-ISSN: 1178-1661 ; DOI: 10.1007/s40271-013-0014-3
Link: http://dx.doi.org/10.1007/s40271-013-0014-3
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: springer_jour10.1007/s40271-013-0014-3
title: Patients’ Willingness-to-Pay for an Alzheimer’s Disease Medication in Canada
format: Article
creator:
  • Oremus, Mark
  • Tarride, Jean-Eric
  • Pullenayegum, Eleanor
  • Clayton, Natasha
  • Raina, Parminder
subjects:
  • Aged–Drug Therapy
  • Aged, 80 and Over–Economics
  • Alzheimer Disease–Statistics & Numerical Data
  • Canada–Statistics & Numerical Data
  • Cost-Benefit Analysis–Statistics & Numerical Data
  • Drug Costs–Statistics & Numerical Data
  • Female–Statistics & Numerical Data
  • Financing, Personal–Statistics & Numerical Data
  • Health Knowledge, Attitudes, Practice–Statistics & Numerical Data
  • Humans–Statistics & Numerical Data
  • Male–Statistics & Numerical Data
  • Patient Acceptance of Health Care–Statistics & Numerical Data
  • Severity of Illness Index–Statistics & Numerical Data
ispartof: The Patient - Patient-Centered Outcomes Research, 2013, Vol.6(3), pp.161-168
description: BACKGROUNDAlzheimer's disease (AD) is a neurodegenerative disorder highlighted by progressive declines in cognition and function. OBJECTIVESThe aim of this article is to assess whether persons with AD would support out-of-pocket payment for an AD medication; to elicit the monthly dollar amounts they would pay. METHODSWe recruited persons with mild or moderate AD (n = 216) from nine clinics across Canada. During one-on-one interviews, we presented our sample with four scenarios describing a medication that either treated disease symptoms or modified the course of AD; each version of the medication was alternatively presented as having a 0 % or 30 % chance of adverse effects. For each scenario, participants indicated whether they would support paying out-of-pocket for the medication (yes/no). Affirmative responses were followed with questions asking participants whether they would pay $75, $150, or $225 (Canadian dollars) per month. RESULTSLevels of support ('yes' responses) ranged from 57 % to 83 % and mean willingness-to-pay ranged from $98 to $137, depending on scenario. Participants were more likely to provide affirmative responses and higher willingness-to-pay amounts when the medication modified disease or had a 0 % chance of adverse effects. Age was inversely associated with support in three scenarios and willingness-to-pay amounts in all four scenarios. Positive associations between post-secondary education and willingness-to-pay amounts were found in three scenarios. CONCLUSIONSPersons with mild or moderate AD were often willing to pay out-of-pocket for AD medications. However, the mean maximum willingness-to-pay ($137) for the optimal medication scenario was lower than the average monthly cost of existing AD medications.
language: eng
source:
identifier: ISSN: 1178-1653 ; E-ISSN: 1178-1661 ; DOI: 10.1007/s40271-013-0014-3
fulltext: fulltext
issn:
  • 1178-1661
  • 11781661
  • 1178-1653
  • 11781653
url: Link


@attributes
ID1462474388
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1007/s40271-013-0014-3
sourceidspringer_jour
recordidTN_springer_jour10.1007/s40271-013-0014-3
sourcesystemPC
pqid1428270108
galeid352257343
display
typearticle
titlePatients’ Willingness-to-Pay for an Alzheimer’s Disease Medication in Canada
creatorOremus, Mark ; Tarride, Jean-Eric ; Pullenayegum, Eleanor ; Clayton, Natasha ; Raina, Parminder
ispartofThe Patient - Patient-Centered Outcomes Research, 2013, Vol.6(3), pp.161-168
identifier
languageeng
source
subject
descriptionBACKGROUNDAlzheimer's disease (AD) is a neurodegenerative disorder highlighted by progressive declines in cognition and function. OBJECTIVESThe aim of this article is to assess whether persons with AD would support out-of-pocket payment for an AD medication; to elicit the monthly dollar amounts they would pay. METHODSWe recruited persons with mild or moderate AD (n = 216) from nine clinics across Canada. During one-on-one interviews, we presented our sample with four scenarios describing a medication that either treated disease symptoms or modified the course of AD; each version of the medication was alternatively presented as having a 0 % or 30 % chance of adverse effects. For each scenario, participants indicated whether they would support paying out-of-pocket for the medication (yes/no). Affirmative responses were followed with questions asking participants whether they would pay $75, $150, or $225 (Canadian dollars) per month. RESULTSLevels of support ('yes' responses) ranged from 57 % to 83 % and mean willingness-to-pay ranged from $98 to $137, depending on scenario. Participants were more likely to provide affirmative responses and higher willingness-to-pay amounts when the medication modified disease or had a 0 % chance of adverse effects. Age was inversely associated with support in three scenarios and willingness-to-pay amounts in all four scenarios. Positive associations between post-secondary education and willingness-to-pay amounts were found in three scenarios. CONCLUSIONSPersons with mild or moderate AD were often willing to pay out-of-pocket for AD medications. However, the mean maximum willingness-to-pay ($137) for the optimal medication scenario was lower than the average monthly cost of existing AD medications.
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://dx.doi.org/10.1007/s40271-013-0014-3$$EView_full_text_in_Springer_(Subscribers_only)
search
creatorcontrib
0Oremus, Mark
1Tarride, Jean-Eric
2Pullenayegum, Eleanor
3Clayton, Natasha
4Raina, Parminder
titlePatients’ Willingness-to-Pay for an Alzheimer’s Disease Medication in Canada
general
010.1007/s40271-013-0014-3
1English
2Springer Science & Business Media B.V.
3SpringerLink
sourceidspringer_jour
recordidspringer_jour10.1007/s40271-013-0014-3
issn
01178-1661
111781661
21178-1653
311781653
rsrctypearticle
creationdate2013
addtitle
0The Patient - Patient-Centered Outcomes Research
1Patient
searchscopespringer_journals_complete
scopespringer_journals_complete
lsr30VSR-Enriched:[galeid, pqid, subject, description, pages]
sort
titlePatients’ Willingness-to-Pay for an Alzheimer’s Disease Medication in Canada
authorOremus, Mark ; Tarride, Jean-Eric ; Pullenayegum, Eleanor ; Clayton, Natasha ; Raina, Parminder
creationdate20130900
facets
frbrgroupid8945053745495680178
frbrtype5
languageeng
creationdate2013
collectionSpringerLink
prefilterarticles
rsrctypearticles
creatorcontrib
0Oremus, Mark
1Tarride, Jean-Eric
2Pullenayegum, Eleanor
3Clayton, Natasha
4Raina, Parminder
jtitlePatient - Patient-Centered Outcomes Research
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Oremus
1Tarride
2Pullenayegum
3Clayton
4Raina
aufirst
0Mark
1Jean-Eric
2Eleanor
3Natasha
4Parminder
au
0Oremus, Mark
1Tarride, Jean-Eric
2Pullenayegum, Eleanor
3Clayton, Natasha
4Raina, Parminder
atitlePatients’ Willingness-to-Pay for an Alzheimer’s Disease Medication in Canada
jtitleThe Patient - Patient-Centered Outcomes Research
stitlePatient
risdate201309
volume6
issue3
spage161
epage168
issn1178-1653
eissn1178-1661
genrearticle
ristypeJOUR
copCham
pubSpringer International Publishing
doi10.1007/s40271-013-0014-3
pages161-168
date2013-09